Published
Video length: 16 min
Guilhem Carayon, vice-president of the Union of Rights for the Republic
Friday October 11, the pharmaceutical company Sanofi announced negotiations with an American investment fund in order to give it control of its subsidiary.
(franceinfo)
Friday October 11, the pharmaceutical company Sanofi announced negotiations with an American investment fund in order to give it control of its subsidiary.
The French pharmaceutical company Sanofi announced on Friday October 11 that it was negotiating with an American investment fund to cede control of its over-the-counter products subsidiary Opella, which notably produces Doliprane, the best-selling drug in France. “We are heading towards a new sale of a French industrial flagship. This is neither good for the health of the French nor good for jobs. We have 900 jobs in Calvados and Oise which are threatened (…) It is also an issue of sovereignty for the French. We thought we were going to learn lessons from the health crisis Obviously not since Emmanuel Macron contradicts himself with his declarations and we are ready to give up. our sovereignty over a product which is vital”explains Guilhem Carayon, vice-president of the Union of Rights for the Republic
“The problem is when the real economy (the production of goods and services that we really need in everyday life) is managed by people who only think about one thing: their dividends. By a purely financial vision “We are no longer responding to social needs.”assures Sophie Taillé-Polian, Génération.s-NFP deputy for Val-de-Marne